Kadmon Holdings Llc (KDMN) Stock Price, Quote, News and Overview
NASDAQ:KDMN - Nasdaq -
KDMN Quote, Performance and Key Statistics
9.5
+0.02 (+0.21%)
The current stock price of KDMN is 9.5 null. In the past month the price increased by 5.67%. In the past year, price increased by 174.57%.
KDMN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About KDMN
Company Profile
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company is headquartered in New York City, New York. The company went IPO on 2016-07-27. The firm's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The company is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The firm has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.
Company Info
Kadmon Holdings Llc
450 E 29th St
New York City NEW YORK 10016 US
CEO: Harlan W. Waksal
Employees: 0
Company Website: http://kadmon.com/
Phone: 18339005366.0
Kadmon Holdings Llc / KDMN FAQ
What is the stock price of Kadmon Holdings Llc today?
The current stock price of KDMN is 9.5 null. The price increased by 0.21% in the last trading session.
What is the ticker symbol for Kadmon Holdings Llc stock?
The exchange symbol of Kadmon Holdings Llc is KDMN and it is listed on the Nasdaq exchange.
On which exchange is KDMN stock listed?
KDMN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Kadmon Holdings Llc stock?
12 analysts have analysed KDMN and the average price target is 12.34 null. This implies a price increase of 29.92% is expected in the next year compared to the current price of 9.5. Check the Kadmon Holdings Llc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Kadmon Holdings Llc worth?
Kadmon Holdings Llc (KDMN) has a market capitalization of 1.63B null. This makes KDMN a Small Cap stock.
How many employees does Kadmon Holdings Llc have?
Kadmon Holdings Llc (KDMN) currently has 0 employees.
What are the support and resistance levels for Kadmon Holdings Llc (KDMN) stock?
Kadmon Holdings Llc (KDMN) has a support level at 8.72 and a resistance level at 9.51. Check the full technical report for a detailed analysis of KDMN support and resistance levels.
Is Kadmon Holdings Llc (KDMN) expected to grow?
The Revenue of Kadmon Holdings Llc (KDMN) is expected to decline by -3.81% in the next year. Check the estimates tab for more information on the KDMN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Kadmon Holdings Llc (KDMN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KDMN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KDMN, evaluating the profitability, health, valuation and growth aspects
- Kadmon Holdings Llc (KDMN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Kadmon Holdings Llc (KDMN) Sales and EPS estimates to see what analysts future expectations are.
- Kadmon Holdings Llc (KDMN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Kadmon Holdings Llc (KDMN) Insider and Institutional Ownership to learn about the owners and their transactions.
- Kadmon Holdings Llc (KDMN) Stock Chart to make your own analysis
- Kadmon Holdings Llc (KDMN) Latest news and press-releases to stay up to date.
Does Kadmon Holdings Llc (KDMN) stock pay dividends?
KDMN does not pay a dividend.
What is the Price/Earnings (PE) ratio of Kadmon Holdings Llc (KDMN)?
Kadmon Holdings Llc (KDMN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
KDMN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KDMN. When comparing the yearly performance of all stocks, KDMN is one of the better performing stocks in the market, outperforming 97.65% of all stocks.
KDMN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KDMN. KDMN has a bad profitability rating. Also its financial health evaluation is rather negative.
KDMN Financial Highlights
Over the last trailing twelve months KDMN reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 28.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -5955.81% | ||
| ROA | -35.84% | ||
| ROE | N/A | ||
| Debt/Equity | 6.96 |
KDMN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to KDMN. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -11.43% and a revenue growth -3.81% for KDMN